Trials / Completed
CompletedNCT00276276
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer
An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control Alone or in Combination With Oral Topotecan in Patients With Relapsed Resistant SCLC
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 141 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them. The study will compare how long patients live when they are given therapy to make them feel better (active symptom control) to the length of time patients live when they are also receiving oral HYCAMTIN.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | topotecan |
Timeline
- Start date
- 2000-11-01
- First posted
- 2006-01-13
- Last updated
- 2013-04-15
Locations
17 sites across 6 countries: Bulgaria, Hungary, Netherlands, Russia, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00276276. Inclusion in this directory is not an endorsement.